AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development With a grant of USD 475,000, the Michael J. Fox Basis is funding preclinical advancement of a vaccine against Parkinson’s disease by AFFiRiS AG Click her . The vaccine, referred to as PD01, targets the protein alpha-synuclein and might offer for the first time a probability for a treatment that can slow or end the progression of Parkinson’s disease. The foundation of PD01 is the company’s AFFITOME technology, which already delivered, amongst others, two vaccines from AFFiRiS AG for the treating Alzheimer’s disease. AFFiRiS AG, located in Vienna, Austria, today announced that among its current nine advancement programs shall receive financing from the united states Michael J.
Hall, AFA’s president and chief executive officer, said the foundation is privileged and honored that President Obama penned a bit for the magazine. As observed by President Obama, advances in the Affordable Treatment Act include: requiring fresh health insurance plans to cover preventive solutions; reducing out-of-pocket charges for prescription medications for Medicare beneficiaries; creating a long-term treatment insurance program that includes home health care; and providing more teaching for long-term care employees. These presssing issues are striking home with an increasing number of Americans. Currently, around 5.1 million Us citizens have Alzheimer’s disease, but the aging population, like the oldest seniors who turn 65 next year, is projected to fuel what some experts possess dubbed a silver tsunami.